Literature DB >> 1792191

Apparently silent somatotroph adenomas.

P Pagesy1, J Y Li, M Kujas, F Peillon, O Delalande, A Visot, P Derome.   

Abstract

We describe here 9 patients with somatotroph adenomas associated with mild features of acromegaly and basal plasma GH levels in the normal range. In 5 women and 4 men, 26 to 61 yrs old, the diagnosis of prolactinoma or non-secreting pituitary adenoma had been previously made on the basis of amenorrhea-galactorrhea or tumoral symptoms. However, they had discrete signs of coarsening of the facial features and moderate but evolutive changes of hand and foot sizes. Basal GH levels were in the normal range (0.4 to 4.5 micrograms/l, N less than 5 micrograms/l) but unaffected by oral glucose and insulin tolerance tests while IGF-I concentrations were elevated in all the cases (range 1.7 to 5.8 U/ml, N: 0.37-1.41 U/ml). Plasma PRL concentrations were elevated in 5 patients (range 16 to 80 micrograms/l, N less than 13 micrograms/l in men and N less than 19 micrograms/l in women). The 9 patients had a macroadenoma with an extrasellar extension in 8 of them and all were operated on by the transsphenoidal route. Immunocytochemical studies demonstrated IRGH-cells in all the adenomas and IRPRL-cells in 5 of them. Electron microscopic analysis of 3 tumors showed that the secretory granules were sparse and the Golgi apparatus poorly developed. Molecular biology of 7 tumors showed the presence of small amounts of GH mRNA. This result was in agreement with the morphological aspect, suggesting a low rate of GH synthesis. Thanks to these different approaches the diagnosis of silent somatotroph adenoma should sometimes be reconsidered.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1792191     DOI: 10.1016/S0344-0338(11)81066-6

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  9 in total

1.  Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.

Authors:  Ozgur Mete; Omalkhaire M Alshaikh; Amber Cintosun; Shereen Ezzat; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2018-12       Impact factor: 3.943

Review 2.  Silent somatotroph pituitary adenomas: an update.

Authors:  Fabienne Langlois; Randall Woltjer; Justin S Cetas; Maria Fleseriu
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

3.  Pituitary adenomas that show a faint GH-immunoreactivity but lack fibrous body: Pit-1 adenoma with endocrinologically low activity.

Authors:  Akiko Yoneda; Toshiaki Sano; Shozo Yamada; Abdulkader Obari; Zhi Rong Qian; Elaine Lu Wang; Naoko Inosita; Eiji Kudo
Journal:  Endocr Pathol       Date:  2010-03       Impact factor: 3.943

4.  Acromegaly with normal growth hormone levels: response to Sandostatin-LAR treatment.

Authors:  I Shimon; D Nass; M Hadani
Journal:  Pituitary       Date:  2000-05       Impact factor: 4.107

5.  Morphological characterization and subtyping of silent somatotroph adenomas.

Authors:  H Naritaka; T Kameya; Y Sato; S Furuhata; M Otani; T Kawase
Journal:  Pituitary       Date:  1999-05       Impact factor: 4.107

6.  Expression of Pit-1 and growth hormone-releasing hormone receptor mRNA in human pituitary adenomas: difference among functioning, silent, and other nonfunctioning adenomas.

Authors:  Ikuo Kobayashi; Hidehiro Oka; Heiji Naritaka; Yuichi Sato; Kiyotaka Fujii; Toru Kameya
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

7.  Pituitary Insulin: Insulin-Like Growth Factors.

Authors:  Shunichi Yokoyama; Lucia Stefaneanu; Kalman Kovacs
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

8.  Transformation of a microprolactinoma into a mixed growth hormone and prolactin-secreting pituitary adenoma.

Authors:  Cédric Dessimoz; Patrick Browaeys; Philippe Maeder; Benoît Lhermitte; Nelly Pitteloud; Shahan Momjian; François P Pralong
Journal:  Front Endocrinol (Lausanne)       Date:  2012-01-12       Impact factor: 5.555

Review 9.  Treatment of Prolactinoma.

Authors:  Warrick J Inder; Christina Jang
Journal:  Medicina (Kaunas)       Date:  2022-08-13       Impact factor: 2.948

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.